1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells

Steroids

Volumn 85, Issue , 2014, Pages 30-35

  Lundqvist, Johan ^a,b   Yde, Christina W ^a   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Breast cancer; Tamoxifen resistance; Vitamin D

Indexed keywords

CALCITRIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; I KAPPA B; I KAPPA B BETA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL GROWTH ASSAY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; MCF 7 CELL LINE; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CALCITRIOL; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; MCF-7 CELLS; NF-KAPPA B; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84899837018     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.04.001     Document Type: Article

References (35)

1. A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
2. S. Ali, and R.C. Coombes Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 2002 101 112 (Pubitemid 37328797)
3. M.L. Auchus, and R.J. Auchus Human steroid biosynthesis for the oncologist J Investig Med 60 2012 495 503
4. J.D. Croxtall, and K. McKeage Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women Drugs 71 2011 363 380
5. C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, and S. Darby et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
6. E.A. Musgrove, and R.L. Sutherland Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 2009 631 643
7. C.W. Yde, K.B. Emdal, B. Guerra, and A.E. Lykkesfeldt NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells Breast Cancer Res Treat 135 2012 67 78
8. Z. Gu, R.Y. Lee, T.C. Skaar, K.B. Bouker, J.N. Welch, and J. Lu et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780) Cancer Res 62 2002 3428 3437 (Pubitemid 34651389)
9. R. Nehra, R.B. Riggins, A.N. Shajahan, A. Zwart, A.C. Crawford, and R. Clarke BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells FASEB J 24 2010 2040 2055
10. L.A. deGraffenried, B. Chandrasekar, W.E. Friedrichs, E. Donzis, J. Silva, and M. Hidalgo et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen Ann Oncol 15 2004 885 890 (Pubitemid 39004343)
11. Y. Zhou, C. Yau, J.W. Gray, K. Chew, S.H. Dairkee, and D.H. Moore et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer BMC Cancer 7 2007 59
12. Y. Zhou, S. Eppenberger-Castori, U. Eppenberger, and C.C. Benz The NFkappaB pathway and endocrine-resistant breast cancer Endocr Relat Cancer 12 Suppl. 1 2005 S37 S46
13. A.V. Krishnan, S. Swami, L. Peng, J. Wang, J. Moreno, and D. Feldman Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy Endocrinology 151 2010 32 42
14. J. Lundqvist, S.K. Hansen, and A.E. Lykkesfeldt Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase Biochim Biophys Acta 1833 2013 40 47
15. S. Swami, A.V. Krishnan, L. Peng, J. Lundqvist, and D. Feldman Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements Endocr Relat Cancer 20 2013 565 577
16. 3 exerts tissue-specific effects on estrogen and androgen metabolism Biochim. Biophys. Acta 1811 2011 263 270
17. 3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer Endocrinology 153 2012 2576 2587
18. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, L. Peng, and M.A. Albertelli et al. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice. Selective modulation of aromatase expression in vivo Horm Cancer 2 2011 190 202
19. J. Welsh Vitamin D and cancer: integration of cellular biology, molecular mechanisms and animal models Scand J Clin Lab Invest Suppl 243 2012 103 111
20. E. Laporta, and J. Welsh Modeling vitamin D actions in triple negative/basal-like breast cancer J Steroid Biochem Mol Biol 14 2013 022
21. J. Welsh Cellular and molecular effects of vitamin D on carcinogenesis Arch Biochem Biophys 523 2012 107 114
22. A.V. Krishnan, S. Swami, and D. Feldman The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer Steroids 77 2012 1107 1112
23. A.V. Krishnan, S. Swami, and D. Feldman Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention J Steroid Biochem Mol Biol 136 2013 289 295
24. S.S. Larsen, I. Heiberg, and A.E. Lykkesfeldt Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells Br J Cancer 84 2001 686 690 (Pubitemid 32239004)
25. G.L. Christensen, J.S. Jepsen, C.K. Fog, I.J. Christensen, and A.E. Lykkesfeldt Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment Breast Cancer Res Treat 85 2004 53 63 (Pubitemid 38437982)
26. C.M. Hansen, K.J. Hamberg, E. Binderup, and L. Binderup Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation Curr Pharm Des 6 2000 803 828 (Pubitemid 30396417)
27. S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling insulin-like growth factor binding protein-3 actions in human disease Endocr Rev 30 2009 417 437
28. A.V. Krishnan, and D. Feldman Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D Annu Rev Pharmacol Toxicol 51 2011 311 336
29. M. Cohen-Lahav, S. Shany, D. Tobvin, C. Chaimovitz, and A. Douvdevani Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels Nephrol Dial Transplant 21 2006 889 897
30. J. Sun, J. Kong, Y. Duan, F.L. Szeto, A. Liao, and J.L. Madara et al. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor Am J Physiol Endocrinol Metab 291 2006 E315 E322
31. M. Schwab, V. Reynders, S. Loitsch, D. Steinhilber, J. Stein, and O. Schroder Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling Mol Immunol 44 2007 3625 3632 (Pubitemid 46817672)
32. P. Briand, and A.E. Lykkesfeldt Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration Cancer Res 44 1984 1114 1119 (Pubitemid 14151513)
33. A.E. Lykkesfeldt, M.W. Madsen, and P. Briand Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell Line, MCF-7/TAMR-1 Cancer Res 54 1994 1587 1595
34. S. Thrane, A.E. Lykkesfeldt, M.S. Larsen, B.S. Sorensen, and C.W. Yde Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling Breast Cancer Res Treat 139 2013 71 80
35. C. Borner, V. Hollt, and J. Kraus Mechanisms of the inhibition of nuclear factor-kappaB by morphine in neuronal cells Mol Pharmacol 81 2012 587 597